StockData
Neumora Therapeutics, Inc. logo

Neumora Therapeutics, Inc. (NMRA) stock

NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 2/30
$0.37−0.06 (-13.85%)

Close on Nov 16, 2026Market cap $69.43MP/E –Yield –

Neumora Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Neumora Therapeutics's net income for the twelve months ending Jun 30, 2026 was -$212.75M. For fiscal 2025 it was -$236.93M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$236.93M–
FY2024Dec 31, 2024-$243.79M–
FY2023Dec 31, 2023-$235.93M–
FY2022Dec 31, 2022-$130.90M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$43.08M–
Q1 FY2026Mar 31, 2026-$53.46M–
Q4 FY2025Dec 31, 2025-$59.45M–
Q3 FY2025Sep 30, 2025-$56.76M–
Q2 FY2025Jun 30, 2025-$52.73M–
Q1 FY2025Mar 31, 2025-$67.99M–
Q4 FY2024Dec 31, 2024-$58.82M–
Q3 FY2024Sep 30, 2024-$72.55M–
Q2 FY2024Jun 30, 2024-$58.70M–
Q1 FY2024Mar 31, 2024-$53.72M–
Q4 FY2023Dec 31, 2023-$108.73M–
Q3 FY2023Sep 30, 2023-$53.03M–
Q2 FY2023Jun 30, 2023-$38.54M–
Q1 FY2023Mar 31, 2023-$35.63M–
Q4 FY2022Dec 31, 2022-$28.15M–
Q3 FY2022Sep 30, 2022-$29.34M–
Q2 FY2022Jun 30, 2022-$30.37M–
Q1 FY2022Mar 31, 2022-$43.04M–

More Neumora Therapeutics figures

See a number that looks wrong?